Adoptive cellular immunotherapy using immune cells expressing chimeric antigen receptors
(CARs) has shown promise, particularly for the treatment of hematological malignancies. To …

The development of novel targeted therapies with acceptable safety profiles is critical to
successful cancer outcomes with better survival rates. Immunotherapy offers promising …

New treatments are needed for B-cell malignancies persisting after allogeneic
hematopoietic stem cell transplantation (alloHSCT). We conducted a clinical trial of …

Immune checkpoint receptors are crucial molecules for fine-tuning immune responses.
Checkpoint signaling dampens T cell activation to avoid autoimmunity and the destructive …

The engineering of T lymphocytes to express chimeric antigen receptors (CARs) aims to
establish T cell-mediated tumor immunity rapidly. In this study, we conducted a pilot clinical …

Despite therapeutic progress in acute myeloid leukemia (AML), relapse post-allogeneic
hematopoietic stem cell transplantation (allo-HSCT) remains a major challenge. Here, we …

Blockbuster antibody therapies have catapulted immune‐based approaches to treat cancer
into the consciousness of mainstay clinical research. On the back of this, other emerging …

Patients with leukemia who receive a T cell–depleted allogeneic stem cell graft followed by
postponed donor lymphocyte infusion (DLI) can experience graft-versus-leukemia (GVL) …

Allogeneic stem cell transplantation (alloSCT) can be a curative treatment for hematological
malignancies. Unfortunately, the desired anti-tumor or graft-versus-leukemia (GvL) effect is …

Previous studies have shown that children with acute myeloid leukemia (AML) who
developed mixed chimerism (MC) were at high risk for relapse after allogeneic stem-cell …